Literature DB >> 30770477

Pharmacology, Part 5: CT and MRI Contrast Media.

Geoffrey M Currie1.   

Abstract

Pharmacology principles provide key understanding that underpins the clinical and research roles of nuclear medicine practitioners. The scope of practice of the nuclear medicine technologist demands knowledge and understanding of indications, contraindications, warnings, precautions, proper use, drug interactions, and adverse reactions for each medication to be used. This article is part of a series that aims to enhance understanding of pharmacologic principles relevant to nuclear medicine. This article will build on the introductory concepts, terminology, and principles of pharmacology explored in the first 2 articles in the series. Specifically, this article will focus on the pharmacologic principles and adverse reactions associated with iodinated and gadolinium contrast media used in CT and MRI, respectively.
© 2019 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  PET/CT; PET/MRI; SPECT/CT; gadolinium; iodinated contrast; pharmacology

Year:  2019        PMID: 30770477     DOI: 10.2967/jnmt.118.220012

Source DB:  PubMed          Journal:  J Nucl Med Technol        ISSN: 0091-4916


  3 in total

1.  MRI as a first-line imaging modality in acute ischemic stroke: a sustainable concept.

Authors:  Katharina Althaus; Jens Dreyhaupt; Sonja Hyrenbach; Elmar H Pinkhardt; Jan Kassubek; Albert C Ludolph
Journal:  Ther Adv Neurol Disord       Date:  2021-08-27       Impact factor: 6.570

2.  The interaction between iodinated X-ray contrast agents and macrocyclic GBCAs provides a signal enhancement in T1 -weighted MR images: Insights into the renal excretion pathways of Gd-HPDO3A and iodixanol in healthy mice.

Authors:  Enza Di Gregorio; Francesca Arena; Eliana Gianolio; Giuseppe Ferrauto; Silvio Aime
Journal:  Magn Reson Med       Date:  2022-03-07       Impact factor: 3.737

3.  A comparative study between CT, MRI, and intraoral US for the evaluation of the depth of invasion in early stage (T1/T2) tongue squamous cell carcinoma.

Authors:  Masaki Takamura; Taichi Kobayashi; Yutaka Nikkuni; Kouji Katsura; Manabu Yamazaki; Satoshi Maruyama; Jun-Ichi Tanuma; Takafumi Hayashi
Journal:  Oral Radiol       Date:  2021-05-10       Impact factor: 1.852

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.